Monday, September 11, 2023 8:38:45 PM
ACCESSWIRE - Fri Aug 4, 4:30AM CDT
https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/19097626/virogentics-inc-provides-update-on-african-project-european-medicine-agency-application-and-clinical-trials-for-application-for-type-2-diabetes/
Barry Kostiner, CEO of Sagaliam, commented, "Enzolytics has assembled an impressive team in Bulgaria, and is benefitting from the European regulators who have supported the accelerated development of therapeutics for the benefit of patients desperately in need of improved efficacy at lower costs. EMA's dedication to fostering a healthy and well-regulated pharmaceutical landscape is truly commendable and deserving of praise. I am looking forward to my meetings with our team in Sofia next month, and contributing to the advancement of the financial, implementation and marketing plan."
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM